HCS Pharma

HCS Pharma

Created using Figma
HCS Pharma shares should be listed on the Frankfurt stock exchange in the next six months. The company is launching a pre-IPO on the European Digital Asset Exchange (EDSX) that will allow investors to buy shares with a 20% discount on the final listing price.

HCS Pharma has already raised more than €2 million with private sales and has recently opened the public sales: https://www.edsx.ch/projects/hcs-pharma

The goal is to raise €7 million to strengthen its position as a developer of regenerative medicine and cellular therapy.
2022. 4. 8.
2022. 6. 8.
100% 완료된
$209 720 767
28% 골 완료된
734 022 685.00 USD
past
  • 1 HCS
    =
    500 USD
토큰 세부 정보
증권 시세 표시기
HCS
총 공급
€ 7 million
토큰 배포
European Digital Asset Exchange | https://www.edsx.ch/projects/hcs-pharma
허용 된 통화
BTC, CHF, EUR, USDT, DOLLAR
최소 기부금
500
TOKEN
기업 세부 정보
등록 된 회사 이름
HCS Pharma SAS
등록 된 국가
France
회사 설립
Jan 1, 2014
보너스 구조
20% discount offered on final share price
추가 세부 사항
플랫폼
eos
카테고리
플랫폼

약 HCS Pharma

HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies. BIOMIMESYS® technology is also requested to be used in cell therapy and regenerative medicine, allowing HCS Pharma to become the leader in all biotechnology industries in the next 5 years. 

풍모

BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions. 

Depending on the organ, extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity). 

BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™. 

기술 정보

HCS Pharma owns 2 cell culture labs and one automation lab equipped with a robotic platform named HAPIx, including 2 confocal HCS systems, ImageXpress micro confocal systems from Molecular Devices, and a ImageXpress micro XLS also from Molecular Devices and a chemical lab for BIOMIMESYS® production.

% name % 로드맵

  • 18 months

  • - 6 months: Development of a sales force in the different countries in Europe.

    - 1 year: New production line set up + Development of a technical support center in Taiwan + fundraising and/or IPO project.

    - 18 months: Presence in the US.
  • 10 Years

  • - In 3 years, from patient cells, we will be able to recreate small diseased organs to test molecules and find the most suitable therapy for personalized medicine.

    - In 5 years, we will be able to find much more effective clinical drug candidates and therefore ultimately treat patients with cancer, Parkinson's disease, or Alzheimer's.

    - In 10 years, we will be able to recreate complete organs for organ transplantation. And from animal cells, we will be able to recreate muscle and therefore cultured meat.

HCS Pharma 팀

검증 됨 25%

주의. 확인되지 않은 회원은 실제로 팀원이 아닌 위험이 있습니다.

Nathalie Maubon
CEO
검증 됨
Elodie Vandenhaute
Project Manager
확인되지 않음
Zied Souguir
Biomaterial Department Manager
확인되지 않음
Gregory Maubon
Chief Development Officer and IA Project Leader
확인되지 않음

고문

검증 됨 100%

Mauro Andriotto
Advisor
검증 됨

HCS Pharma 인터뷰

Mauro Andriotto
As a team member, сan you tell us about your role in the ICO project?
I am the CEO of the European Digital Assets Exchange where HCS Pharma is listed on the primary market.
What do you think about idea?
It's an amazing company selected by the European Commission between the most 50 most disruptive biotech in Europe and there is the plan to list the company on the Frankfurt Stock Exchange by the end of the year.
Nathalie Maubon
As a team member, сan you tell us about your role in the ICO project?
We have decided to go public before the end of the year by a Reverse Take Over (RTO) with a pre-IPO fund-raising such as STO. This STO in pre-IPO will give the possibility to crypto investors to be onboarded.
What do you think about idea?
This STO coupled with the STO makes it possible to rally virtual currency investors with the traditional market.

HCS Pharma 최근 뉴스

  • 정보 업데이트에는 시간차가있을 수 있으므로 각 ICO 프로젝트에 대한 정확한 정보는 공식 웹 사이트 또는 기타 커뮤니케이션 채널을 통해 확인해야합니다.
  • 이 정보는 ICO 기금 투자에 대한 제안이나 조언이 아닙니다. 관련 정보를 철저히 조사하고 ICO 참여를 결정하십시오.
  • 이 콘텐츠에 대해 수정해야 할 문제 또는 문제가 있다고 생각되거나 자신의 ICO 프로젝트를 제출하고자 할 경우 이메일을 보내주십시오. a>
면책 조항 및 위험 경고를 읽으십시오. 면책 조항 및 위험 경고 표시.